Edward A. Stadtmauer, MD, discusses the evolving treatment landscape in multiple myeloma.
Edward A. Stadtmauer, MD
Advertisement
Articles by Edward A. Stadtmauer, MD
Edward A. Stadtmauer, MD, discusses what makes BCMA a unique target in multiple myeloma.
Edward A. Stadtmauer, MD, section chief, Hematologic Malignancies, and Roseman, Tart, Harrow, and Shaffer Families’ President’s Distinguished Professor, Penn Medicine, University of Pennsylvania, discusses promising targets in multiple myeloma.
Edward A. Stadtmauer, MD, discusses the use of selinexor in patients with heavily pretreated, relapsed/refractory multiple myeloma.
Advertisement
Latest Updated Articles
Dr. Stadtmauer on Current Challenges With Multiple MyelomaPublished: November 3rd 2017 | Updated:
Dr. Stadtmauer Discusses Promising Targets in Multiple MyelomaPublished: October 29th 2019 | Updated:
Dr. Stadtmauer on BCMA-Targeting in Multiple MyelomaPublished: November 26th 2019 | Updated:
Dr. Stadtmauer on Utility of Selinexor in Multiple MyelomaPublished: October 4th 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma
5